Travere Therapeutics Inc Earnings

The next earnings date for Travere Therapeutics Inc is November 5, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Travere Therapeutics Inc Earnings

Report DateEstimated Earnings Per Share
11/05/2025$-0.22

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Travere Therapeutics Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
07/30/2025Before Market------
05/05/2025Before Market$-0.1951.81%
02/13/2025Before Market$-0.47-24.14%
10/31/2024Before Market$-0.70-2.94%
08/01/2024After Market$-0.91-5.81%
05/06/2024After Market$-1.76-77.78%
03/12/2024After Market$-1.187.09%
11/07/2023After Market$-1.17-735.71%
08/03/2023After Market$-1.132.59%
05/04/2023After Market$-1.27-8.55%
02/23/2023After Market$-1.033.74%
10/27/2022After Market$-1.09-26.74%
08/04/2022Before Market$-1.05-19.32%
05/05/2022After Market$-1.20-41.18%
01/10/2022Before Market$-0.84-23.53%
10/28/2021After Market$-0.59-9.26%
07/29/2021After Market$-0.645.88%
05/06/2021After Market$-0.96-146.15%
03/01/2021After Market$-0.48-2.13%
11/05/2020After Market$-0.4415.38%
07/30/2020After Market$-0.58-3.57%
05/11/2020After Market$0.02102.99%
02/24/2020After Market$-0.70-9.38%
10/30/2019After Market$-0.5547.62%
08/06/2019After Market$-0.92-43.75%
05/07/2019After Market$-0.81-42.11%
02/26/2019After Market$-0.1862.50%
11/01/2018After Market$-0.92-104.44%
07/26/2018After Market$-0.56-60.00%
05/01/2018After Market$-0.46-2.22%
02/27/2018After Market$-0.45-136.84%
11/07/2017After Market$-0.46-84.00%
08/09/2017After Market$-0.34-61.90%
05/04/2017After Market$-0.29-11.54%
03/01/2017After Market$-0.2311.54%
11/03/2016After Market$-0.86-326.32%
08/04/2016After Market$-0.37-60.87%
05/03/2016After Market$0.38272.73%
02/25/2016After Market$-0.0766.67%
11/03/2015After Market$0.23-86.06%
08/04/2015After Market$-0.59-40.48%
05/11/2015After Market$-1.43-320.59%
03/05/2015After Market$-1.10-116.25%
11/13/2014After Market$-0.89---
08/12/2014---$-0.90---
05/14/2014---$-0.73-65.91%
03/27/2014---$-0.76-153.33%
11/18/2013---$-0.60-233.33%
08/28/2013---$-0.41---
05/29/2013---$-0.44---
11/30/2011---$-0.00---
08/31/2011---$-0.03---
05/31/2011---$-0.03---
02/28/2011---$-0.04---
11/30/2010---$-0.05---
08/31/2010---$-0.06---
05/31/2010---$-0.06---
02/28/2010---$-0.07---
11/30/2009---$-0.06---
08/31/2009---$-0.06---
05/31/2009---$-0.07---
02/28/2009---$-0.07---
11/30/2008---$-0.04---
08/31/2008---$-0.03---
05/31/2008---$-0.03---

More About Travere Therapeutics Inc

Website
https://www.travere.com
Country
USA
Full Time Employees
385

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

“Travere Therapeutics Inc Earnings” Can Refer to the Travere Therapeutics Inc Earnings Date

Some people say “Travere Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Travere Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Travere Therapeutics Inc Stock on the Earnings Date

If you own Travere Therapeutics Inc stock (TVTX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Travere Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Travere Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Travere Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about Travere Therapeutics Inc earnings or anything else related to the stock market.